Results 111 to 120 of about 28,560,894 (288)
ABSTRACT Objective For multiple disorders, DSM‐5‐TR criteria include “recurrent” engagement in behaviors—for example, in the criteria for binge‐eating disorder (BED), “binge eating is not associated with the recurrent use of inappropriate compensatory behavior.”—without operationalizing how frequently a behavior needs to occur to be considered ...
Sophie R. Abber +12 more
wiley +1 more source
Objective Glucagon-like peptide-1 receptor agonists are established for weight management and cardiovascular risk reduction, with emerging evidence for kidney protection.
Rong Huang, Bin Wang
doaj +1 more source
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou +7 more
wiley +1 more source
Objective: One of the most important pathophysiological changes occurring in obese patients is systemic inflammation. This study aims to examine the relationship between C-reactive protein (an inflammatory marker), anti-inflammatory adiponectin, and ...
Zeynel Abidin SAYİNER +2 more
doaj
Glucagon-like peptide 1 is a hormone involved in the regulation of glucose. Glucose-dependent activation of brain GLP-1R stimulates GLP-1 secretion from the L-cells of the intestine in response to ingested nutrients and it enters the blood stream to ...
Robinson, Louise E.
core
Structure, measurement, and secretion of human glucagon-like peptide-2
Glucagon-like peptide-2, human peptide ...
Hartmann, Bolette +5 more
core +1 more source
Current and potential use of GLP-1R agonists: beyond type 2 diabetes
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins ...
Graciela Zambrano-Galván +3 more
doaj +1 more source
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hamish Courtney,1 Rahul Nayar,2 Chinnadorai Rajeswaran,3 Ravi Jandhyala 4 1Diabetes Department, Royal Victoria Hospital, Belfast, 2City Hospitals Sunderland NHS Foundation Trust, Sunderland, 3Department of Diabetes & Endocrinology, Mid Yorkshire NHS ...
Rajeswaran C +3 more
core

